Mabwell’s Nectin-4 targeted ADC 9MW2821 combination therapy demonstrates 87.5% ORR and granted CDE Breakthrough Therapy...

China’s National Medical Products Administration (NMPA) approves Padcev in combination with Keytruda (Pembrolizumab) for the...

GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or...

Araris Biotech announces research collaboration and option to license agreement with Chugai Pharmaceutical to develop...

Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development

PostEra announces expansion to $610M in their AI drug discovery collaboration with Pfizer